As SRC inhibitors perform poorly as single anti‐cancer agents in most cancers tested (for example [9]), we next sought to identify potential resistance mechanisms that rely upon SRC that could be targeted with drug combination therapy using AZD0424. This evidence concerns the gene SRC and cancer.